The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations.
 
Sumanta K. Pal
No Relationships to Disclose
 
Siamak Daneshmand
No Relationships to Disclose
 
Surena F. Matin
No Relationships to Disclose
 
Yohann Loriot
No Relationships to Disclose
 
Srikala S. Sridhar
No Relationships to Disclose
 
Petros Grivas
No Relationships to Disclose
 
Shilpa Gupta
No Relationships to Disclose
 
Guru Sonpavde
No Relationships to Disclose
 
Mark T. Fleming
No Relationships to Disclose
 
Seth P. Lerner
No Relationships to Disclose
 
Craig Berman
No Relationships to Disclose
 
Jessica Rearden
No Relationships to Disclose
 
Yining Ye
No Relationships to Disclose
 
Hiywot Takkele
No Relationships to Disclose
 
Susan Moran
No Relationships to Disclose
 
Joaquim Bellmunt
No Relationships to Disclose